Prior Authorization for Medications
MPC Pharmacy Rx Prior Authorization Process:
Prior authorization requests for covered outpatient medications are processed by the MPC Pharmacy Department. The MPC Pharmacy PA department can be reached directly at 1-888-258-8250. Providers are encouraged to continue to submit electronic prior authorizations (ePA) via their existing vendor (i.e. CoverMyMeds/Surescript). To find the appropriate prior authorization form, see the list below for the prior authorization forms for outpatient pharmacy medications. Please fax completed prior authorization forms, with supporting clinical documentation, to the MPC Pharmacy PA department at 1-833-896-0656.
Please note that behavioral health and abuse deterrent medications are “carved out” from MPC and are payable as fee-for-service (FFS) through Maryland Medical Assistance. Refer to the following link to the Maryland Department of Health formulary to confirm coverage under FFS: MDH BH Formulary
Prior Authorization Pharmacy Forms
- Actemra Subq
- Acthar Gel
- Adalimumab Products (Hadlima, Yusimry, Adalimumab-adbm, Hulio, Amjevita, Simlandi, Cyltezo, Abrilada, Hyrimoz, Yuflyma, Idacio, Humira)
- Adapalene and Tretinoin
- Adbry
- Aimovig
- Ajovy
- Arcalyst
- Arikayce
- Austedo
- Avonex, Betaseron, Copaxone, Extavia, Glatopa
- Benlysta SQ
- Benznidazole
- Bylvay
- Cablivi
- Cambia
- Camzyos
- Cayston
- CCR5 – Anatgonist
- Celecoxib
- Chelating Agents (Oral Iron Chelators)
- Cialis 2.5mg and 5mg
- Cibinqo
- Cimzi
- Cinqair
- Clonidine ER and Guanfacine ER
- Combination HIV Single-Tablet
- Cortophin
- Cosentyx
- Cresemba
- Cystagon, Procysbi
- Daliresp
- Daraprim
- Daybue
- Descovy
- Diabetic Testing Supplies (Glucometers)
- Diabetic Testing Supplies (Test Strips QL)
- Diabetic Testing Supplies (Test Strips)
- Dimethyl Fumarate
- Direct Renin Inhibitors
- Doptelet
- DPP4 Inhibitors
- Duavee
- Dupixent
- Duvyzat
- Egrifta
- Emflaza
- Emgality
- Enbrel
- Enspryng
- Entresto
- Eohilia
- Evrysdi
- Fabhalta
- Fasenra
- Fertility Preservation
- Filspari
- Firazyr, Sajazir, Icatibant
- Forteo
- Gender Affirming Care
- Global Non-Formulary
- Global Quantity Limit
- Global Step Therapy
- GLP-1 Products (Trulicity, Rybelsus, Liraglutide, Byetta, Mounjaro, Ozempic, Bydureon)
- GnRH Analogs
- Gralise
- Grastek, Oralair
- Growth Hormones
- Haegarda
- Hetlioz
- Hyperlipidemia
- Idiopathic Pulmonary Fibrosis Agents
- Ilaris
- Ilumya
- Increlex
- Insulin Pen
- Intravaginal Progesterone
- Javygtor, Kuvan, Sapropterin
- Joenja
- Juxtapid
- Kalydeco
- Kesimpta
- Keveyis, Ormalvi, Dichlorphenamide
- Kevzara
- Kineret
- Kitabis Pak
- Korlym
- Lidocaine Patch
- Linezolid (Oral)
- Livmarli
- Livtencity
- Lokelma
- Long Acting Opioids (Belbuca, Butrans, Fentanyl, Morphine ER, Oxycodone ER, Oxycontin, Hysingla, Methadone, Nucynta ER, Oxymorphone ER)
- Lumryz, Xyrem, Xywav
- Lupkynis
- Mavenclad
- Movantik
- Mulpleta
- Multaq
- Myalept
- Natroba, Sklice
- Nitisone
- NNRTI
- NRTI
- Nucala
- Nuplazid
- Nuzyra
- Ocaliva
- Olumiant
- Omnipod
- Omnitrope
- Onychomycosis
- Oral Anticoagulants (Eliquis)
- Oral MS Agents
- Orencia Subq
- Orenitram
- Orfadin, Nityr
- Orilissa
- Orkambi
- Orladeyo
- Otezla
- Oxervate
- Palynziq
- Phenylbutyrate Products
- Platelet Inhibitors (Effient, Brilinta, Zontivity)
- PPI ODT, Packets, Sprinkles
- PPI Quantity Limit
- PPI Tablets, Capsules
- Pradaxa
- Praluent
- Prevymis
- Promacta
- Protease Inhibitors
- Pulmonary Hypertension Agents
- Pulmozyme
- Radicava
- Rectiv
- Remodulin
- Repatha
- Restasis, Xiidra
- Reyvow
- Rinvoq
- Rukobia
- Rybelsus, Trulicity
- Savaysa
- Savella
- SGTL2 Inhibitor Products (Dapagliflozin, Inpefa, Invokamet, Invokamet XR, Invokana, Jardiance, Segluromet, Steglatro, Synjardy, Xigduo XR )
- Short Acting Opioids (Morphine IR, Hydromorphone, Oxycodone IR, Nucynta IR, Tramadol IR, Hydrocodone-Apap, Apap-Codeine)
- Siliq
- Simponi Subq
- Skyclarys
- Skyrizi IV-Subq, On-body
- Sohonos
- Solaraze
- Somavert
- Sotyktu
- Stelara
- Strensiq
- Symdeko
- Symlin
- Synagis
- Takhzyro
- Taltz
- Tarpeyo
- Tavalisse
- Testosterone Agents
- Tezspire
- Tobi Podhaler
- Topical Collagenase Santyl
- Topical Hyaluronic Acid Agents
- Topical NSAIDs
- Topical Quantity Limits
- Tranexamic Acid
- Tremfya
- Tryvio
- Tymlos
- Tyvaso DPI
- Uptravi
- Vancomycin (Oral)
- Veletri
- Vemlidy
- Ventavis, Tyvaso
- Veozah
- Voxzogo
- Wegovy
- Xarelto
- Xeljanz
- Xolair
- Zavesca
- Zeposia
- Zokinvy
MPC Medical Benefit Drug Prior Authorization Request Process (Buy & Bill)
Prior authorization for medications reviewed by Maryland Physicians Care must be submitted using the
Medical Benefit Drug Prior Authorization Form.
For MPC Clinical Policies click here
- Actemra IV RX-PA-048
- Acute Hereditary Angioedema Products RX-PA-001
- Adakveo RX-PA-003
- Alpha1-Proteinase Inhibitors RX-PA-004
- Altuviiio RX-PA-086
- Apretude (cabotegravir) RX-PA-058
- Benlysta IV (belimumab) RX-PA-050
- Beqvez RX-PA-098
- Botox, Dysport, Myobloc, Xeomin RX-PA-005
- Briumvi RX-PA-080
- Cabenuva RX-PA-006
- Cinryze, Haegarda RX-PA-007
- Crysvita RX-PA-060
- Cubicin RX-PA-045
- Dalvance RX-PA-043
- Empaveli RX-PA-039
- Enjaymo RX-PA-075
- Entyvio (vedolizumab) RX-PA-008
- ESA Products RX-PA-065
- Exondys 51 and Vyondys 53 RX-PA-009
- Gattex (Teduglutide) RX-PA-010
- Givlaari RX-PA-091
- Glucocerebrosidase Replacement Enzymes (Ceremyze and VPRIV) RX-PA-011
- GnRH Agonists & Antagonists RX-PA-012
- Granulocyte Colony-Stimulating Factors RX-PA-013
- Hemgenix RX-PA-083
- Hemlibra RX-PA-099
- High Cost Low Volume Drug Risk Mitigation Policy RX-PA-014
- Hyaluronic Acid Derivatives RX-PA-015
- Infliximab Products RX-PA-016
- Intravenous Immune Globulin (IVIG) & Subcutaneous Immune Globulin (SCIG) RX-PA-017
- IV and Injectable Iron Products RX-PA-044
- Jivi RX-PA-100
- Juxtapid and Evkeeza RX-PA-040
- Kanuma (sebelipase alfa) RX-PA-019
- Korsuva RX-PA-074
- Kyrstexxa (Pegloticase) RX-PA-020
- Lamzede® RX-PA-088
- Lemtrada (alemtuzumab) RX-PA-047
- Leqembi RX-PA-081
- Leqvio RX.PA.068
- Luxturna RX-PA-089
- Mucopolysaccharidosis Agents RX-PA-021
- Nplate (Romiplostim) RX-PA-023
- Nulibry® (fosdenopterin) RX-PA-041
- Nulojix (Belatacept) RX-PA-024
- Nuzyra for Injection RX-PA-061
- Ocrevus RX-PA-025
- Ocular Disorders RX-PA-026
- Ocular Implants RX-PA-018
- Onpattro RX-PA-027
- Orencia IV RX-PA-052
- Osteoporosis Injectables RX-PA-028
- Oxlumo® (lumasiran) RX-PA-042
- Prevymis IV RX-PA-069
- Pulmonary Arterial Hypertension (PAH) Products RX-PA-029
- Rethymic RX-PA-063
- Revcovi RX-PA-002
- Rituxan (rituximab) RX-PA-030
- Roctavian RX-PA-084
- Ryplazim RX-PA-067
- Saphnelo RX-PA-072
- Signifor (Pasireotide) RX-PA-031
- Simponi Aria RX-PA-073
- Skysona RX-PA-090
- Soliris (Eculizumab) RX-PA-032
- Specialty Drug Management RX-PA-033
- Specialty Enzymes RX-PA-034
- Spinraza RX-PA-035
- Sunlenca RX-PA-082
- Tepezza RX-PA-064
- Treatment Optimization RX-PA-101
- Tysabri (natalizumab) RX-PA-036
- Ultomiris RX-PA-054
- Vyepti RX-PA-046
- Vyjuvek RX-PA-087
- Xenpozyme RX-PA-085
- Xiaflex (Collagenase Clostridium Histolyticum) MP-097
- Zolgensma RX-PA-038
- Zynteglo RX-PA-071
Non-Formulary Exception Process
To support routine non-Formulary pharmacy authorization decisions, MPC uses guidelines based on FDA-approved indications, evidence-based clinical literature, recognized off-label use supported by peer-reviewed clinical studies, and member’s benefit design, which are applied based on individual members.
The Non-Formulary Guideline is used to evaluate authorization requests for which there are no specific guidelines. A request may be authorized if the medications are deemed to be medically necessary for any of the following reasons:
- up to two (2) formulary drugs (when available) in the same therapeutic category have been utilized for an adequate trial and have not been effective,
- formulary drugs in the same therapeutic category are contra-indicated, or
- there is no therapeutic alternative listed on the Formulary.
To request a non-formulary exception, call the MPC Pharmacy PA Department at 1-888-258-8250.
Specialty Medications
Prior authorization review for specialty medications is based on the pharmacy benefit used for the distribution of the medication.
Oncology Medications
Eviti will process prior Authorization for medications related to an oncology treatment regimen. Your office can sign up for training at https://connect.eviti.com to learn how to access the web-based system. If you have any additional questions, please call Eviti, Inc., our oncology vendor, at 1-888-678-0990 (toll-free).
Request for authorization for oncology medications off-label use will be processed through Maryland Physicians Care.
Hepatitis C Medications
Hepatitis C drug prior authorizations are processed by MPC’s Pharmacy Department using the Maryland Department of Health (MDH) Hepatitis C clinical criteria. Fax the completed MDH Hepatitis C Prior Authorization Form with clinical information to 800-953-8856.
MPC Pharmacy Prior Authorization Search Tool
Using the look-up tool, providers can confirm which medications are covered under the pharmacy benefit and which medications require prior authorization.
For medications covered under the medical benefit, please use the MPC Prior Authorization form: Medical Benefit Drug Prior Auth Form.
Formulary Search ToolName | Formulary Status | Eviti PA | MPC PA | 90 Day |
---|